A Coruna

• "Neoadjuvant phase II study of pembrolizumab and carboplatin plus paclitaxel for stage I triple-negative breast cancer (The TELESCOPE study) … Ended recruitment
  2024-513511-27-00 4 2025-05-29 HR-negative/HER2-negative resectable stage I TNBC.
• Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors Ended recruitment
  2024-513307-13-00 4 2025-05-26 Advanced/metastatic solid tumors including gynecological cancers (endo
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended recruitment
  2024-512925-95-00 5 2025-05-16 Advanced/Metastatic Breast Cancer
• A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended recruitment
  2024-516609-22-00 5 2025-04-15 Primary Sjögren’s Disease
• A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended recruitment
  2023-509239-19-00 5 2025-04-03 Active Psoriatic Arthritis
• A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active … Ended recruitment
  2024-516213-20-00 5 2025-03-25 Psoriatic arthritis
• Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN) Ended recruitment
  2024-515538-34-00 10 2025-02-27 Head and Neck Squamous Cell Carcinoma
• A research study to investigate the effects of CagriSema compared to placebo in people with type 2 diabetes and painful diabetic peripheral … Ended recruitment
  2023-509662-38-00 4 2025-01-22 Type 2 diabetes and painful diabetic peripheral neuropathy
• Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppres … Ended recruitment
  2024-514046-37-00 5 2025-01-16 HIV-1 Infection
• Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer After Platinum-Based Chemother … Ended recruitment
  2024-511957-23-00 5 2025-01-03 Recurrent or Persistent Endometrial Cancer
• Study to evaluate the use of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line t … Ended recruitment
  2024-514728-17-00 11 2024-12-30 Advanced or recurrent endometrial cancer
• A study to learn how well bimekizumab works and how safe it is in adults with psoriatic arthritis Ended recruitment
  2024-511738-11-00 5 2024-12-18 Psoriatic arthritis
• Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Subjects With Type 2 Diabetes Mell … Ended recruitment
  2024-513539-25-00 4 2024-11-22 Type 2 Diabetes Mellitus
• A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheu … Ended recruitment
  2023-508077-85-00 5 2024-11-19 Polymyalgia Rheumatica
• Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study) Ended recruitment
  2023-509301-80-00 5 2024-11-04 Severe hypertriglyceridemia (SHTG)
• Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (MUIR-3 Study) Ended recruitment
  2023-509302-30-00 5 2024-11-04 Hypertriglyceridemia
• A study to continue providing GME751 (a new medicine that is similar to pembrolizumab) to participants who are eligible for pembrolizumab tr … Ended recruitment
  2024-513160-25-00 5 2024-10-30 Melanoma and Non-small-cell lung cancer
• A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Ref … Ended recruitment
  2024-516149-38-00 4 2024-10-29 Hodgkin Lymphoma
• A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation Ended recruitment
  2023-503714-77-00 4 2024-10-01 Advanced Non-Small Cell Lung Cancer
• A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended recruitment
  2023-504753-12-00 5 2024-10-01 Lung Cancer, Non-Small Cell
• A Phase III study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus Ended recruitment
  2023-503692-24-00 5 2024-09-25 Cutaneous Lupus Erythematosus
• PROSPER: clinical Phase 2 study to test how safe and effective is a new medicine called FNP-223 to slow disease progression of progressive s … Ended recruitment
  2023-510366-28-00 4 2024-09-25 Progressive supranuclear palsy (PSP)
• A study to determine if ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy (IgAN) Ended recruitment
  2023-507851-31-00 5 2024-09-23 Immunoglobulin A Nephropathy (IgAN)
• A Phase 2a Study of Efinopegdutide in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis Ended recruitment
  2024-510923-20-00 4 2024-09-16 Metabolic Dysfunction-Associated Steatohepatitis

Showing 265–288 of 558 trials